Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Pulmonary Arterial Hypertension Market Growth in 2025?

The market size of pulmonary arterial hypertension has seen substantial growth over the past few years. The market, which stood at $8.47 billion in 2024, is projected to expand to $9.24 billion in 2025, maintaining a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historic period is credited to factors such as heightened awareness and diagnosis of pulmonary arterial hypertension (PAH), an increase in healthcare spending, a growing elderly population, expansion of treatment options for pulmonary arterial hypertension, and an increase in research and development activities targeting pulmonary hypertension.

What Is the Forecast for the Pulmonary Arterial Hypertension Market Size Through 2029?

The market size of pulmonary arterial hypertension is predicted to experience significant growth in the upcoming years. It is projected to reach $12.97 billion in 2029 with a compound annual growth rate (CAGR) of 8.8%. This growth over the forecast period is due to the implementation of new treatment methods for pulmonary arterial hypertension, heightened emphasis on early detection and diagnosis, an expanding pipeline of PAH medications and therapies, the incorporation of precision medicine in treating PAH, and the growth of the healthcare infrastructure in emerging markets. Key trends in the forecast period involve developments in medical imaging and diagnosis technologies, cooperative efforts and partnerships in drug development, patient-focused tactics in managing pulmonary arterial hypertension, and a rise in the utilization of combination therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp

What are the Key Market Players in Pulmonary Arterial Hypertension Market and How They’re Evolving?

Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

What Are the Primary Growth Drivers in the Pulmonary Arterial Hypertension Market?

The surge in the occurrence of pulmonary arterial hypertension (PAH) disease plays a significant role in driving the growth of the pulmonary arterial hypertension market. The burgeoning cases of PAH and the subsequent hospitalization for its treatment are anticipated to amplify the need for associated drugs in the forecast years. As per a research work disseminated by the National Organization for Rare Disorders, Inc., the USA witnesses PAH emerging in one to two individuals per million annually, which is equivalent to 500–1000 new cases each year. Europe is projected to demonstrate similar incidence rates.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp

What Are the Leading Segments in the Global Pulmonary Arterial Hypertension Industry?

The pulmonary arterial hypertension market covered in this report is segmented –

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators

2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational

3) By Distribution channel: Retail, Online

Subsegments:

1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan

2) By PDE-5 Inhibitors: Sildenafil, Tadalafil

3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost

4) By SGC Stimulators: Riociguat

What Are the Key Market Trends in the Pulmonary Arterial Hypertension Industry?

Leading firms in the pulmonary arterial hypertension market are developing and introducing innovative products like Winrevair to enhance treatment choices and outcomes for those afflicted by this serious ailment. For example, Merck & Co. Inc., an American multi-national pharmaceutical firm, launched Winrevair for treating adults with pulmonary arterial hypertension in March 2024. Winrevair, the first therapy approved by the US-based federal agency Food and Drug Administration (FDA) that targets activin signaling for pulmonary arterial hypertension, operates by re-establishing the equilibrium between pro- and anti-proliferative signals; this helps in controlling the vascular cell proliferation related with PAH. Consequently, it presents a new category of therapy for dealing with this disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

What Is the Regional Outlook for the Pulmonary Arterial Hypertension Market?

North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5954

This Report Delivers Insight On:

1. How big is the pulmonary arterial hypertension market, and how is it changing globally?

2. Who are the major companies in the pulmonary arterial hypertension market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary arterial hypertension market right now?

4. Which products or customer segments are growing the most in the pulmonary arterial hypertension market?

5. What factors are helping or slowing down the growth of the pulmonary arterial hypertension market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model